Yongrenxin is a research and development product introduced from Japan by Chongqing Yongrenxin Medical Device Co., Ltd., which was put into production in Chongqing on 20 14, and its clinical trial began on 20 18. 15 patients have been successfully implanted, all patients have recovered without serious clinical complications, and then successfully listed with the approval of the state.
It is understood that the price of artificial heart in the international market is 800,000 to 1 10,000 yuan, which is a huge economic burden for the families of ordinary patients. After domestic mass production, the price will drop by about 30% compared with international prices such as the United States and Japan. The price is relatively favorable, which can greatly reduce the economic burden of patients.
It is reported that the "Yongrenxin" ventricular assist device is on the market, and the sales volume is expected to reach10 million next year. The third-generation artificial heart developed in China is also expected to be listed in two years, and it still needs a long way to be widely popularized in clinic. Because the artificial heart is implanted into the human body as an artificial instrument, there are still many thorny problems to be faced.
An artificial heart is equivalent to a pump implanted in the human body, through which blood is delivered to the whole body. It is understood that the blood flowing through the artificial pump may also cause thrombosis; The artificial pump needs to be connected to the power supply to run, and the wound with external wires on the skin may form infection; Patients with advanced heart failure will also have different physical characteristics and conditions, and complications may occur after implantation, and complications may also be different. These problems will restrict the wide application of artificial heart.